Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: pathophysiologic foundation and clinical findings.
The pathophysiologic basis for potent platelet inhibition in the acute coronary syndromes has been established. In the setting of PTCA for unstable angina and non-Q-wave myocardial infarction, there are clear data for a benefit of GP IIb/IIIa inhibition, whereas for primary PTCA in evolving myocardial infarction, preliminary data are very encouraging and a large-scale clinical trial is nearly completed. Glycoprotein IIb/IIIa inhibition as an adjunct to medical therapy for unstable angina is also the subject of encouraging preliminary data, and 3 large-scale clinical trials have just been completed. Preliminary data have also been accrued for GP IIb/IIIa inhibition as conjunctive therapy with thrombolytic agents, and large clinical trials are now commencing.
Baylor College of Medicine and the Methodist Hospital, Houston, Tex, USA.
N S
NS
Kleiman
A M
AM
Lincoff
E M
EM
Ohman
R A
RA
Harrington
D000208:Acute Disease; D000789:Angina, Unstable / Q000188:drug therapy / Q000378:metabolism; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000188:drug therapy* / Q000378:metabolism* / Q000503:physiopathology; D006329:Heart Conduction System / Q000187:drug effects; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy / Q000378:metabolism; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D013577:Syndrome; D015912:Thrombolytic Therapy
D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex